Multivessel PCI decreases reinfarction risk in STEMI patients: JACC
USA: Multivessel PCI versus culprit-vessel only PCI lowers risk for reinfarction without any difference in all-cause mortality in STEMI patients, according to a recent study published in the journal JACC: Cardiovascular Interventions. The study included patients with STEMI and multivessel CAD who underwent PCI, it found that those who had multivessel PCI had a lower reinfarction rate than those who had culprit-vessel-only PCI.
About one-half of the patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease (CAD). Randomized controlled trials comparing multivessel and culprit vessel–only PCI have yielded conflicting results regarding the benefits of a multivessel PCI strategy.
The goal of this systematic review and meta-analysis by Varunsiri Atti, Department of Internal Medicine, Michigan State University, Lansing, Michigan, and colleagues was to provide a comprehensive evaluation of contemporary randomized trials that addressed the safety and efficacy of multivessel versus culprit vessel–only percutaneous coronary intervention (PCI) among patients with STEMI and multivessel CAD.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.